Literature DB >> 25108083

Novel homozygous mutations in the osteoprotegerin gene TNFRSF11B in two unrelated patients with juvenile Paget's disease.

Dorit Naot1, Ally Choi2, David Shaun Musson3, Pelin Özlem Simsek Kiper4, Gulen Eda Utine5, Koray Boduroglu6, Munro Peacock7, Linda A DiMeglio8, Tim Cundy9.   

Abstract

Most patients with juvenile Paget's disease (JPD) are homozygous for mutations in the gene TNFRSF11B that result in deficiency of osteoprotegerin (OPG) - a key regulator of bone turnover. So far, about 10 different OPG mutations have been described. The current study presents two novel OPG mutations in JPD patients. Patient 1 was diagnosed at the age of 9months when he presented with inability to sit up, slow growth, marked bone pain and very high levels of serum alkaline phosphatase. Patient 2 presented a milder phenotype. He was initially diagnosed with osteogenesis imperfecta, and although he had numerous fractures and bone deformity, he was still independently mobile at the age of 19years, when a diagnosis of JPD was confirmed. Sequence analysis of DNA samples from the patients determined two novel homozygous mutations in TNFSRF11B. Patient 1 (severe phenotype) had a large (245-251kbp) homozygous deletion beginning in intron 1 that resulted in loss of 4 of the 5 exons of TNFSRF11B, including the whole ligand-binding domain. Patient 2 had a homozygous missense mutation resulting in a Thr>Pro change in exon 2 of TNFSRF11B that is predicted to disrupt the OPG ligand-binding domain. Taken in conjunction with other published cases, these results are consistent with the hypothesis that the most severe phenotypes in JPD are seen in patients with major gene deletions or mutations affecting cysteine residues in the ligand-binding domain.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Genotype–phenotype; Rare bone diseases; Skeletal deformity

Mesh:

Substances:

Year:  2014        PMID: 25108083     DOI: 10.1016/j.bone.2014.07.034

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  3 in total

1.  Acquired resistance to pamidronate treated effectively with zoledronate in juvenile Paget's disease.

Authors:  E N Gonc; A Ozon; G Buyukyilmaz; A Alikasifoglu; O P Simsek; N Kandemir
Journal:  Osteoporos Int       Date:  2018-03-03       Impact factor: 4.507

Review 2.  Rare Inherited forms of Paget's Disease and Related Syndromes.

Authors:  Stuart H Ralston; J Paul Taylor
Journal:  Calcif Tissue Int       Date:  2019-02-13       Impact factor: 4.333

3.  Mutations in Profilin 1 Cause Early-Onset Paget's Disease of Bone With Giant Cell Tumors.

Authors:  Zhe Wei; Shanshan Li; Xiaohui Tao; Guoying Zhu; Zhenkui Sun; Zhanying Wei; Qiong Jiao; Huizhen Zhang; Lin Chen; Baojie Li; Zhenlin Zhang; Hua Yue
Journal:  J Bone Miner Res       Date:  2021-03-10       Impact factor: 6.741

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.